Article
Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Oct 2023
Versluis Jurjen, Saber Wael, Tsai Harrison K, Gibson Christopher J, Dillon Laura W, Mishra Asmita, McGuirk Joseph, Maziarz Richard T, Westervelt Peter, Hegde Pranay, Mukherjee Devdeep, Martens Michael J, Logan Brent, Horowitz Mary, Hourigan Christopher S, Nakamura Ryotaro, Cutler Corey, Lindsley R Coleman
Abstract excerpt
PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival (OS). We evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v no donor) study. METHODS: We performed targeted sequencing in 309 patients age 50-75 years with International Prognostic Scoring System (IPSS) intermediate-2 or high-risk MDS,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.